MAPT and Alzheimer disease: Based on amyloid and tau synergistic endophenotype findings, Fang et al., identified that sildenafil usage was significantly associated with ≈ 30% to 60% reduced risk of AD, using retrospective case–control pharmacoepidemiologic analyses of insurance claims data for 7.23 million older individuals.7